U.S. Markets open in 3 hrs 51 mins

Repare Therapeutics Inc. (RPTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.98+0.12 (+0.50%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close23.86
Open23.86
Bid21.00 x 1200
Ask26.37 x 1100
Day's Range23.34 - 24.95
52 Week Range21.45 - 34.00
Volume31,517
Avg. Volume339,496
Market Cap879.301M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.67
  • Business Wire

    Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500

    Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the first patient has been dosed in the Phase 1/2 clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific genome instability-related genomic alterations including those in ATM gene (ataxia teleangectasia mutated kinase). The multi-center trial will enroll patients with advanced solid tumors of any histology that harbor gene alterations that suggest sensitivity to ATR inhibition as discovered by Repare’s proprietary SNIPRx® platform. Dosing follows acceptance by the U.S. Food and Drug Administration (FDA) of the Company’s investigational new drug (IND) application earlier this month.

  • H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount
    CNW Group

    H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount

    H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount

  • Barrons.com

    Leaf Group, Forma Therapeutics See Activist Action

    Oak Investment Partners disclosed a large stake in digital-content provider Leaf Group. Forma Therapeutics said it owns more than nine million shares of biopharmaceutical firm Forma.